Experimental CAR-T therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT05694364
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 14 times
Summary
This early-phase study tested an experimental therapy called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The main goal was to find the safest dose and see if the treatment could shrink tumors. Because this is a cell therapy that may require ongoing monitoring, it is classified as disease control rather than a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.